Castle Biosciences CSTL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's additional paid-in capital?
- Castle Biosciences (CSTL) reported additional paid-in capital of $700.26M in Q1 2026.
- How has Castle Biosciences's additional paid-in capital changed year-over-year?
- Castle Biosciences's additional paid-in capital increased by 5.1% year-over-year, from $666.12M to $700.26M.
- What is the long-term trend for Castle Biosciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Castle Biosciences's additional paid-in capital has grown at a 7.8% compound annual growth rate (CAGR), from $478.16M to $694.86M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.